ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between February 25 and August 25, 2026 — a 1900% increase over the single deal recorded in the prior six-month window (August 25, 2025 to February 25, 2026). This is not a gradual recovery or a cyclical uptick. This is a land grab, driven by Big Pharma's urgent need to backfill oncology pipelines after a wave of ADC patent cliffs and clinical validations proved the modality's commercial ceiling is far higher than consensus models projected three years ago.

The Data — ADC Deal Activity, Period over Period

The raw numbers speak for themselves. A single deal in six months signals a frozen market — caution, pipeline reassessment, or simply a lack of assets worth licensing. Twenty deals in the subsequent period signals the opposite: competitive urgency so intense that multiple acquirers are bidding simultaneously on overlapping target-payload combinations. If you track Deal Benchmarks on our platform, you'll see this rate of acceleration has no precedent in any modality over the past five years.

What's Driving the Trend

Pipeline gaps are the primary catalyst. Enhertu's dominance in HER2-expressing tumors validated the thesis that next-generation ADCs with novel linker-payload chemistries can generate blockbuster revenues — Daiichi Sankyo/AstraZeneca's franchise is on pace to exceed $14B in cumulative global sales by end of 2026. That proof of concept forced every top-20 pharma company to confront the same question: where is our ADC franchise? For GSK, Novartis, and others, the answer was external. Internal programs take 5–7 years to reach registrational trials. Licensing takes 90 days to close.

Regulatory momentum compounded the urgency. The FDA granted accelerated approvals to three ADC programs in 2025 and issued favorable guidance on bioanalytical methods for site-specific conjugation in Q1 2026. That guidance reduced development risk for next-generation ADCs using novel conjugation platforms — exactly the type of technology Myricx Bio and Biocytogen offer. When regulatory tailwinds align with commercial proof points, capital moves fast. ADC licensing 2026 volumes reflect that convergence.

The capital environment also matters, though it's secondary. Biotech financing improved modestly through H1 2026, with IPO proceeds up roughly 30% year-over-year according to EvaluatePharma data. That gave smaller ADC developers the runway to advance programs to inflection points — IND filings, Phase 1 data, or novel payload disclosures — that make them licensable. The bottleneck in H2 2025 wasn't a lack of buyer interest. It was a lack of licensable assets at the right stage. That bottleneck cleared.

Notable Deals

The Hansoh-GSK deal is the marquee transaction. A $185M upfront — roughly 10.9% of the $1.7B total deal value — signals GSK's confidence in the asset's near-term clinical readout. That upfront-to-TDV ratio sits above the median for oncology licensing deals tracked in our Deal Benchmarks database, which hovered around 8–9% through H1 2026. GSK paid a premium because it needed to. The company has publicly acknowledged its oncology pipeline thinning post-Zejula and has been an aggressive acquirer of external assets across modalities.

Novartis's dual-deal structure with Myricx Bio is equally telling. Two separate agreements — one at $1.5B TDV, the other at $1.1B — covering distinct programs from the same licensor. This is a platform bet, not an asset-level transaction. Novartis is buying access to Myricx's proprietary payload technology, then applying it across multiple targets. When a buyer structures deals this way, it signals they view the underlying technology as a competitive moat, not a one-shot opportunity. Expect more platform-level ADC deals to follow this template.

Whitehawk's double-dip on Biocytogen assets is harder to read without disclosed upfronts, but the pattern is consistent: emerging acquirers are moving into ADC assets at lower entry points, hoping to capture value as the modality continues to validate clinically. The $500M TDV on one of these deals suggests early-stage or preclinical assets — a risk-on bet that makes sense only if you believe ADC deal trends 2026 represent a structural shift, not a cyclical blip.

What This Means for BD Teams Right Now

This is a seller's market — unambiguously. Twenty deals in six months means multiple qualified buyers are competing for a finite pool of differentiated ADC platforms. If you are a biotech with a novel linker-payload chemistry, a differentiated target, or a site-specific conjugation approach with IND-enabling data, your leverage is at a multi-year high. Do not accept the first term sheet. Run a structured process.

Upfront percentages are compressing as TDVs inflate. The Hansoh-GSK deal's 10.9% upfront-to-TDV ratio is generous by historical standards, but we expect that ratio to drift downward as total deal values climb past $2B. Buyers will push more value into milestones to manage risk, which means sellers need to scrutinize milestone achievability with the same rigor they apply to upfront cash. Use the Ambrosia calculator to model how milestone probability adjustments affect your net present value.

For buyers: speed is your only edge. If you're running a 6-month diligence process on an ADC asset, you will lose to a competitor who closes in 90 days with a clean term sheet. The deals above all clustered in a 3-day window in July 2026. That's not coincidence — it's competitive pressure forcing parallel negotiations to simultaneous close. Pre-position your diligence teams. Have payload toxicology experts on retainer. Structure your governance so you can approve a $150M+ upfront in two board meetings, not four.

Platform deals will command premiums over single-asset licenses. The Novartis-Myricx structure is the template going forward. If you're a biotech, frame your technology as a platform — multiple targets, multiple payloads, multiple indications — and you'll access higher TDVs and stronger upfront economics. Single-asset ADC deals will still get done, but they'll trade at a discount to platform transactions.

Benchmark your deal against current market rates using the Ambrosia calculator. ADC deal trends 2026 have moved the goalposts on what constitutes a fair upfront, a reasonable milestone structure, and a competitive royalty tier. If you're negotiating with 2024 comps, you're leaving money on the table.